Our aim is to show that development of new therapeutic strategies/molecules may come from transversal-type
research, in particular from experience in autoimmunity, as immune responses leading to autoimmunity and graft rejection involve similar pathways.”
“We present the case of a 37-year-old nulliparous woman in whom acute massive uterine bleeding during dienogest therapy was successfully treated using intrauterine balloon tamponade. Abnormal uterine bleeding and several cases of profuse bleeding causing severe anemia in association with dienogest therapy have been reported, but this is the first reported case involving hypovolemic shock. While successful control of postpartum hemorrhage with intrauterine balloon tamponade has been well described, applications for non-obstetric bleeding, particularly in the presence of underlying diseases, such as adenomyosis, have only rarely been reported. This procedure can be easily, promptly, and safely implemented R406 cost without Dinaciclib clinical trial analgesia, anesthesia, or laparotomy; it can be used with a minimally dilated external cervical os or narrow uterine cavity; and it can preserve fertility.”
“Purpose of review
Multipotent mesenchymal stromal cells (MSCs) possess powerful immunomodulatory activity highlighting
the potential for their clinical translation in solid organ transplantation. In this review, we summarize recent advances in understanding MSC immunomodulatory effect in vitro and in experimental transplant models and discuss topics of crucial importance for the future clinical use of MSCs as immunotherapy in solid organ transplantation.
MSCs strongly inhibited T-cell activity in vitro and exerted similar inhibitory effects on other cells of the immune system. MSC-mediated
immune suppression has been SBI-0206965 mouse attributed mainly to the secretion of soluble factors; however, cell-contact mechanisms cannot be excluded. Available studies in animal transplant models raised variable results, but overall indicate that MSCs could be useful to modulate recipient immune cells. The timing of cell application and the origin of MSCs (autologous or allogeneic) seem to be the most crucial factors impacting the in-vivo efficacy of MSCs.
A better understanding of the mechanisms underlying the immunomodulatory effects of MSCs in vitro and in vivo is needed to define the optimal condition for the use of MSCs as immunotherapy in solid organ transplantation.”
“A high cure rate of ovarian germ cell tumors was achieved by establishment of a cisplatin-containing regimen. We encountered a rare case of a 33-year-old, nulligravida Japanese woman with systemic thromboembolism following anti-cancer chemotherapy with cisplatin, etoposide, and bleomycin in ovarian germ cell tumor. She suffered from brain infarction, multiple embolisms in the bilateral pulmonary artery and pelvic vein, and a broad range of deep vein thromboses in the right extremities vein.